Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant...

Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France

Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer ( Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Osimertinib plus chemotherapy shows superior results versus osimertinib alone...

Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )

OncoAlert Round Up for September 1-7, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 1-7, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 7: Similarities and Differences ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 8: How PARP inhibitors are being used now ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 9: What PARP inhibitors mean for the future and what to look out for ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Global Focus on Cancer

Dr Anna Cabanes - Global Research and Advocacy Advisor, Global Focus on Cancer

Global Focus on Cancer ( Dr Anna Cabanes - Global Research and Advocacy Advisor, Global Focus on Cancer )

Update from ASCO Breakthrough Asia Conference 2023

Dr Roselle de Guzman - Manila Central University-FDTMF Hospital, Manila...

Update from ASCO Breakthrough Asia Conference 2023 ( Dr Roselle de Guzman - Manila Central University-FDTMF Hospital, Manila, Philippines )

The impact of SEABCS 2023

Dr Heather White - Executive Director, TogetHER for Health

The impact of SEABCS 2023 ( Dr Heather White - Executive Director, TogetHER for Health )

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Dr Linda Malkas - City of Hope, Duarte, USA

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours ( Dr Linda Malkas - City of Hope, Duarte, USA )

More from ecancer